Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated:  11/30/2016
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated: 11/30/2016
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated:  11/30/2016
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated: 11/30/2016
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated:  11/30/2016
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated: 11/30/2016
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated:  11/30/2016
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
Phase I/II Study Of Concurrent Chemotherapy And Escalating Doses Of Radiotherapy (RT) For Unresectable Non-Small Cell Lung Cancer (NSCLC) Using A New RT Paradigm
Status: Enrolling
Updated: 11/30/2016
Franciscan Skemp Healthcare - La Crosse Campus
mi
from
La Crosse, WI
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Palo Alto, CA
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
San Francisco, CA
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Louisville, KY
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Minneapolis, MN
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Omaha, NE
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Portland, OR
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Memphis, TN
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated:  11/30/2016
Clinical Research Facility
mi
from
Lubbock, TX
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
Status: Enrolling
Updated: 11/30/2016
Clinical Research Facility
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated:  12/1/2016
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated: 12/1/2016
University Cancer Institute, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated:  12/1/2016
Northeast Georgia Cancer Care, LLC
mi
from
Boynton Beach, FL
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated: 12/1/2016
Northeast Georgia Cancer Care, LLC
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated:  12/1/2016
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Erlangen,
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy
Status: Enrolling
Updated: 12/1/2016
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Erlangen,
Click here to add this to my saved trials
Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
Status: Enrolling
Updated:  12/1/2016
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer
A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
Status: Enrolling
Updated: 12/1/2016
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies
Status: Enrolling
Updated:  12/1/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) (NSC 701852) in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies
Status: Enrolling
Updated: 12/1/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated:  12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Pillars4Life Trial
Pillars4Life Randomized Control Trial
Status: Enrolling
Updated: 12/6/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy
Novel Tumor Vaccine gp96-Ig Fusion Protein in Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed First Line Chemotherapy
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated:  12/14/2016
Clinical Research Facility
mi
from
New York, NY
A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients
A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated: 12/14/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Stylet vs No Stylet During EBUS TBNA
Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)
Status: Enrolling
Updated:  12/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Stylet vs No Stylet During EBUS TBNA
Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)
Status: Enrolling
Updated: 12/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated:  12/14/2016
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated: 12/14/2016
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan
Status: Enrolling
Updated:  12/15/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan
Status: Enrolling
Updated: 12/15/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Status: Enrolling
Updated:  12/15/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Status: Enrolling
Updated: 12/15/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/28/2016
North Central Cancer Treatment Group
mi
from
Rochester, MN
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/28/2016
North Central Cancer Treatment Group
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated:  1/3/2017
University of Chicago Medical Center
mi
from
Chicago, IL
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated: 1/3/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated:  1/3/2017
Memorial Sloane Kettering Cancer Center
mi
from
New York, NY
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated: 1/3/2017
Memorial Sloane Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated:  1/3/2017
The University of Leicester
mi
from
Leicester,
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma
Status: Enrolling
Updated: 1/3/2017
The University of Leicester
mi
from
Leicester,
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Cotton-O'Neil Clinical Research Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
University of Louisville Hospital
mi
from
Louisville, KY
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Massachusetts General Hospital
mi
from
Cambridge, MD
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Massachusetts General Hospital
mi
from
Cambridge, MD
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Oncology/Hematology P.C.
mi
from
Rockville, MD
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Oncology/Hematology P.C.
mi
from
Rockville, MD
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Washington University
mi
from
St. Louis, MO
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Highlands Oncology Group
mi
from
Fayetteville, NC
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Highlands Oncology Group
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Promedica Health System
mi
from
Toledo, OH
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Promedica Health System
mi
from
Toledo, OH
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Abington Hematology Oncology Associates
mi
from
Willow Grove, PA
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Texas Oncology, P.A. - Abilene (South)
mi
from
Abilene, TX
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Texas Oncology, P.A. - Abilene (South)
mi
from
Abilene, TX
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  1/4/2017
ZNA Middelheim
mi
from
Antwerpen,
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 1/4/2017
ZNA Middelheim
mi
from
Antwerpen,
Click here to add this to my saved trials
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated:  1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Internet-based System for Cancer Patients to Self-report Toxicity
Pilot Study of STAR, an Internet-based System for Cancer Patients to Self-report Toxicity Symptoms, Performance Status, and Quality of Life
Status: Enrolling
Updated: 1/9/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated:  1/12/2017
Clinical Research Facility
mi
from
New York, NY
Safety Study of AMG 228 to Treat Solid Tumors
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status: Enrolling
Updated: 1/12/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials